Proteome Analysis of Maternal Serum Samples for Trisomy 21 Pregnancies Using ProteinChip Arrays and Bioinformatics

Busch, Anne; Michel, Susanne; Hoppe, Constance; Driesch, Dominik; Claussen, Uwe; Eggeling, Ferdinand von

doi:10.1369/jhc.4b6377.2005

Cited by 26 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The search identified four such studies [7][8][9][10] , but one of these did not report a list of potential biomarkers [7] . One firsttrimester study identified seven potential biomarkers [10] , but in a subsequent validation study only one of the proteins (epidermal growth factor) was significantly decreased in maternal serum from trisomy 21 pregnancies [11] .…”

Section: Literature Searchmentioning

confidence: 99%

Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

Mastricci

Akolekar²,

Kuppusamy³

et al. 2011

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: The aim of this study is to identify potential biomarkers for fetal trisomy 21 from previous publications using proteomic techniques and examine the potential value of such biomarkers in early screening for this aneuploidy. Methods: This was a case-control study of 25 pregnancies with fetal trisomy 21 and 50 euploid controls undergoing first-trimester screening for aneuploidies by a combination of maternal age, fetal nuchal translucency (NT) thickness and maternal serum free β-human chorionic gonadotrophin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A). The maternal serum concentrations of afamin, apolipoprotein E, clusterin, ceruloplasmin, epidermal growth factor, fetuin-A, pigment epithelium-derived factor glycoprotein and transthyretin were determined using an ELISA and compared in the euploid and trisomy 21 groups. Results: In pregnancies with fetal trisomy 21, the median maternal age, fetal NT thickness and serum free β-hCG were increased, whereas serum PAPP-A was decreased. However, there were no significant differences between cases and controls in any of the biomarkers. Conclusion: Proteins identified as potential biomarkers for trisomy 21 using proteomic techniques have not been found to be useful in early screening for this aneuploidy.

show abstract

Section: Literature Searchmentioning

confidence: 99%

Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

Mastricci

Akolekar²,

Kuppusamy³

et al. 2011

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…The current first trimester combined test is based on enzyme-linked immunosorbent assay (ELISA) methods, which is widely used for quantitative protein measurements. Recently, two-dimensional gel electrophoresis (2-D), tandem mass spectrometry (MS-MS) and bead-based multiplexed immunoassays have been used to identify several potential biomarkers in amniotic fluid and maternal blood (Busch et al, 2005, Kolialexi et al, 2008, Nagalla et al, 2007, Tsangaris et al, 2006, clearly demonstrating the potential of applying proteomics techniques in the quest for new biomarkers. Bead-based multiplexed immunoassays use color-coded tiny beads in up to 100 distinct sets.…”

Section: Future Perspectives and Ongoing Researchmentioning

confidence: 99%

Innovations in Down Syndrome Screening

Koster¹,

Vries²,

Visser³

et al. 2011

Prenatal Diagnosis and Screening for Down Syndrome

View full text Add to dashboard Cite

“…In contrast to serum (Busch et al 2005), the analysis of tissues or fractionated cells is more time-consuming because microdissection or cell sorting is necessary; however, the chance of finding a reliable tumor marker might be higher than in serum (Melle et al 2005). As a minimum, there is a greater chance to obtain more information about the biological mechanisms leading to the genesis and progression of cancer.…”

Section: Discussionmentioning

confidence: 99%

Proteohistography–Direct Analysis of Tissue with High Sensitivity and High Spatial Resolution Using ProteinChip Technology

Ernst

Melle

Schimmel

et al. 2006

J Histochem Cytochem.

Self Cite

View full text Add to dashboard Cite

On the proteomic level, all tissues, tissue constituents, or even single cells are heterogeneous, but the biological relevance of this cannot be adequately investigated with any currently available technique. The analysis of proteins of small tissue areas by any proteomic approach is limited by the number of required cells. Increasing the number of cells only serves to lower the spatial resolution of expressed proteins. To enhance sensitivity and spatial resolution we developed Proteohistography. Laser microdissection was used to mark special areas of interest on tissue sections attached to glass slides. These areas were positioned under microscopic control directly on an affinity chromatographic ProteinChip Array so that cells were lysed and their released proteins bound on a spatially defined point. The ProteinChip System, surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), allows the laser to be steered to up to 215 distinct positions across the surface of the spot, enabling a high spatial resolution of measured protein profiles for the analyzed tissue area. Protein profiles of the single positions were visually plotted over the used tissue section to visualize distribution proteohistologically. Results show that the spatial distribution of detectable proteins could be used as a Proteohistogram for a given tissue area. Consequently, this procedure can provide additional information to both a matrix-assisted laser desorption/ionization (MALDI)-based approach and immunohistochemistry, as it is more sensitive, highly quantitative, and no specific antibody is needed. Hence, proteomic heterogeneity can be visualized even if proteins are not known or identified.

show abstract

Proteome Analysis of Maternal Serum Samples for Trisomy 21 Pregnancies Using ProteinChip Arrays and Bioinformatics

Cited by 26 publications

References 15 publications

Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

Innovations in Down Syndrome Screening

Proteohistography–Direct Analysis of Tissue with High Sensitivity and High Spatial Resolution Using ProteinChip Technology

Contact Info

Product

Resources

About